OMNIULTRA
LIVE

Serial Number

99477945

Owner

Crystal Bioscience, Inc.

Attorney

Francis P. Cislak

Filing Date

Nov 4, 2025

Add to watchlist:

No watchlists yet
View on USPTO

OMNIULTRA Trademark

Serial Number: 99477945

OMNIULTRA is a trademark filed by Crystal Bioscience, Inc. on November 4, 2025. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 40 (Treatment & Processing), Class 42 (Computer & Scientific). The application is currently pending registration.

Owner Contact Info

Crystal Bioscience, Inc. (2 trademarks)

5980 Horton Street
Emeryville, CA 94608

Entity Type: 03

Trademark Details

Filing Date

November 4, 2025

Registration Date

Not Registered

Goods & Services

synthesized peptides for scientific and research use; for research purposes, excluding those for medical or veterinary use; proteins and synthesized peptides used in the research, product development, and manufacture of pharmaceuticals; chemical reagents for use in evaluating genetic material, namely, the detection, measurement and identification of genetic materials and their compounds, excluding those for medical and veterinary use; biological tissue, namely, animal tissue for use in scientific and medical research; cells for scientific and research use; stem cells for scientific and research use; antibodies for use in further scientific and medical research

synthesized peptides for medical use, namely, for the treatment of viral diseases, respiratory diseases, autoimmune diseases, immune diseases, inflammatory diseases, dermatological diseases, cancer, endocrine diseases, heptalogical diseases, pain, infectious diseases, metabolic diseases and disorders; biological reagents for medical use; chemical reagents for medical use, namely, for the detection, measurement and identification of genetic materials; biological tissue cultures, namely, animal tissue cultures for medical purposes; antibodies for medical; radiopharmaceutical compositions for medical diagnostic or therapeutic use, namely, diagnostic radiopharmaceutical preparations and radiopharmaceuticals for the diagnosis or treatment of cancer, cardiovascular disease, lung disease, thyroid disease, bone disease, brain disease, and bodily tissue disease; synthesized peptides for use in drug discovery of pharmaceuticals for the treatment of viral diseases, respiratory diseases, autoimmune diseases, immune diseases, inflammatory diseases, dermatological diseases, cancer, endocrine diseases, heptalogical diseases, pain, infectious diseases, metabolic diseases and disorders; chemical preparations for use in drug discovery for the treatment of viral diseases, respiratory diseases, autoimmune diseases, immune diseases, inflammatory diseases, dermatological diseases, cancer, endocrine diseases, heptalogical diseases, pain, infectious diseases, metabolic diseases and disorders; pharmaceutical preparations for use in the treatment of medical conditions, namely, suppressing tumors; diagnostic preparations for medical purposes; pharmaceutical preparations in the nature of synthesized peptides for use in drug discovery and pharmaceuticals for the treatment of for medical purposes; synthesized proteins and chemical preparations for use in drug discovery and pharmaceuticals for the treatment of viral diseases, respiratory diseases, autoimmune diseases, immune diseases, inflammatory diseases, dermatological diseases, cancer, endocrine diseases, heptalogical diseases, pain, infectious diseases, metabolic diseases and disorders

Scientific research services in the field of the analysis and synthesis of peptides and antibodies; Scientific research services in the field of the analysis and synthesis of proteins; quality control of peptides and antibodies used in drug development; advice on quality control of peptides and antibodies used in drug development; scientific research and development; scientific research and development in the field of immunization and antibody screening

manufacture of synthetic peptides and antibodies to the order and specification of others; peptide and antibody synthesis for others, namely, manufacture of synthetic peptides and antibodies to the order and specification of others

Filing History

TEAS/EMAIL CORRESPONDENCE ENTERED
Jun 30, 2026 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jun 30, 2026 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jun 30, 2026 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Mar 30, 2026 GNRN
NON-FINAL ACTION E-MAILED
Mar 30, 2026 GNRT
NON-FINAL ACTION WRITTEN
Mar 30, 2026 CNRT
ASSIGNED TO EXAMINER
Mar 17, 2026 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Feb 12, 2026 NWOS
APPLICATION FILING RECEIPT MAILED
Nov 4, 2025 MAFR
NEW APPLICATION ENTERED
Nov 4, 2025 NWAP